Skip to main content

Phathom Pharmaceuticals, Inc.

PHAT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001783183

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of PHAT: Q1 2026 compared with Q2 2026
MeasureQ1 2026Of which not filed for Q2 2026Q2 2026Change
Holders1742161−11
Shares68.9M23.4K72.1M+3.21M (+4.7%)
Value$765.5M$260.1K$782.1M+$16.9M (+2.2%)

2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (21)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to PHAT in Q2 2026
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.1,022,193$11.1M0.02%
HSBC Holdings PLC709,695$7.70M0.00%
Jane Street Group, LLC212,706$2.31M0.00%
Opaleye Management Inc.185,589$2.01M0.18%
Jones Hill Capital LP161,486$1.75M0.37%
Schroder Investment Management Group101,745$1.11M0.00%
Arrowstreet Capital, Limited Partnership77,316$838.9K0.00%
Pale Fire Capital SE49,713$539.4K0.04%
Quantbot Technologies LP42,755$463.9K0.02%
Nomura Holdings Inc40,000$434.0K0.00%
Y-Intercept (Hong Kong) Ltd39,845$432.3K0.01%
Wealth Enhancement Advisory Services, LLC18,731$236.2K0.00%
Jupiter Topco LLC21,500$233.2K0.00%
Rafferty Asset Management, LLC12,756$138.4K0.00%
Fulcrum Asset Management LLP4,458$48.5K0.00%
Aster Capital Management (DIFC) Ltd508$5.51K0.00%
Fifth Third Bancorp218$2.37K0.00%
Quarry LP127$1.38K0.00%
Silver Grove Financial Group, Inc.81$8790.00%
SRS Capital Advisors, Inc.42$4560.00%
Clearstead Advisors, LLC5$550.00%

Sold out (32)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Not filed for Q2 2026 yet (2)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PHAT in Q1 2026 that haven't filed for Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
Janus Henderson Group PLC21,500$239.4K
CWM, LLC1,864$20.7K